| abstract |
Terlipressin for use in the treatment of hepatorenal syndrome type 1 (HRS-1) in a patient who does not have overt sepsis, septic shock or uncontrolled infection and who meets two or more of the following three criteria (i)-(iii) for systemic inflammatory response syndrome (SIRS): (i) a white blood cell count that is either less than 4,000 cells/mm3 or greater than 12,000 cells/mm3, (ii) a heart rate greater than 90 beats per minute, and ( iii) either HCO3 < 23 mmol/L or PaCO2 < 32 mm Hg in blood or > 20 breaths per minute, where the amount of terlipressin used is effective to produce a reduction in serum creatinine of at least 25 % from baseline, HRS reversal, and/or confirmed HRS reversal. |